Literature DB >> 19062198

Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder.

Kai G Kahl1, Susanne Bens, Kristin Ziegler, Sebastian Rudolf, Andreas Kordon, Leif Dibbelt, Ulrich Schweiger.   

Abstract

BACKGROUND: Major depression has been associated with endocrine and immune alterations, in particular a dysregulation of the hypothalamus-pituitary-adrenal system with subsequent hypercortisolism and an imbalance of pro- and anti-inflammatory cytokines. Recent studies suggest that vascular endothelial growth factor (VEGF), a cytokine involved in angiogenesis and neurogenesis, may also be dysregulated during stress and depression. These observations prompted us to examine VEGF and other angiogenic factors in patients with major depressive disorder.
METHODS: Twelve medication-free female patients with a major depressive episode in the context of borderline personality disorder (MDD/BPD) and twelve healthy women were included. Concentrations of VEGF, VEGF receptors 1 and 2, basic fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF), angiopoetin-2, interleukin-8 (IL-8) and transforming growth factor-beta1 (TGF-beta1) were determined from serum profiles.
RESULTS: Increased concentrations of VEGF and FGF-2 were found in MDD/BPD patients compared to the healthy comparator group. No group differences were found concerning the other angiogenic factors examined.
CONCLUSION: Depressive episodes in the context of borderline personality disorder may be accompanied by increased serum concentrations of VEGF and FGF-2. Similar findings have been observed in patients with major depression without a borderline personality disorder. A dysregulation of angiogenic factors may be another facet of the endocrine and immunologic disturbances frequently seen in patients with depressive episodes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19062198     DOI: 10.1016/j.psyneuen.2008.09.016

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  32 in total

1.  Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study.

Authors:  Kai G Kahl; Wiebke Greggersen; Ulrich Schweiger; Joachim Cordes; Christoph U Correll; Helge Frieling; Chakrapani Balijepalli; Christian Lösch; Susanne Moebus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-07-10       Impact factor: 5.270

2.  A Systematic Review of Personality Disorders and Health Outcomes.

Authors:  Katherine L Dixon-Gordon; Diana J Whalen; Brianne K Layden; Alexander L Chapman
Journal:  Can Psychol       Date:  2015-10-15

Review 3.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

4.  Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer.

Authors:  Carolyn Y Fang; Brian L Egleston; John A Ridge; Miriam N Lango; Dana H Bovbjerg; Jamie L Studts; Barbara A Burtness; Margret B Einarson; Andres J P Klein-Szanto
Journal:  Head Neck       Date:  2013-10-26       Impact factor: 3.147

Review 5.  Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.

Authors:  Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

6.  A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.

Authors:  Erica M Richards; Daniel C Mathews; David A Luckenbaugh; Dawn F Ionescu; Rodrigo Machado-Vieira; Mark J Niciu; Wallace C Duncan; Neal M Nolan; Jose A Franco-Chaves; Thomas Hudzik; Carla Maciag; Shuang Li; Alan Cross; Mark A Smith; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

7.  Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Depression Correlates with Severity of Disease.

Authors:  A J Russo
Journal:  Biomark Insights       Date:  2010-08-03

Review 8.  Vascular growth factors in neuropsychiatry.

Authors:  Samuel S Newton; Neil M Fournier; Ronald S Duman
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 9.  The fibroblast growth factor family: neuromodulation of affective behavior.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

10.  Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features.

Authors:  Zeynep Kotan; Emre Sarandöl; Emine Kırhan; Güven Ozkaya; Selcçuk Kırlı
Journal:  Ther Adv Psychopharmacol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.